261 related articles for article (PubMed ID: 24807631)
1. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
[TBL] [Abstract][Full Text] [Related]
2. Clusterin expression in medullary thyroid carcinoma is inversely correlated with the presence of lymph node metastases.
Mourra N; Bennis M; Boelle PY; Cochand-Priollet B; Lefevre M; Lepine C; Balaton A; Klijanienko J; Menegaux F; Tissier F
Hum Pathol; 2017 Jun; 64():37-43. PubMed ID: 28411179
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
5. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.
Czeczok TW; Stashek KM; Maxwell JE; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):94-100. PubMed ID: 29420353
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
[TBL] [Abstract][Full Text] [Related]
7. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours.
Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A
Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308
[TBL] [Abstract][Full Text] [Related]
8. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
[TBL] [Abstract][Full Text] [Related]
9. Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours.
Mourra N; Couvelard A; Tiret E; Olschwang S; Flejou JF
Histopathology; 2007 Feb; 50(3):331-7. PubMed ID: 17257128
[TBL] [Abstract][Full Text] [Related]
10. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours.
Jernman J; Välimäki MJ; Louhimo J; Haglund C; Arola J
Neuroendocrinology; 2012; 95(4):317-24. PubMed ID: 22327359
[TBL] [Abstract][Full Text] [Related]
11. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
12. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
13. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
15. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.
Perry KD; Reynolds C; Rosen DG; Edgerton ME; T Albarracin C; Gilcrease MZ; Sahin AA; Abraham SC; Wu Y
Histopathology; 2011 Oct; 59(4):619-30. PubMed ID: 22014043
[TBL] [Abstract][Full Text] [Related]
16. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Carcinoids and Low-Grade Gastrointestinal Neuroendocrine Tumors Show Common MicroRNA Expression Profiles, Different from Adenocarcinomas and Small Cell Carcinomas.
Yoshimoto T; Motoi N; Yamamoto N; Nagano H; Ushijima M; Matsuura M; Okumura S; Yamaguchi T; Fukayama M; Ishikawa Y
Neuroendocrinology; 2018; 106(1):47-57. PubMed ID: 28208131
[TBL] [Abstract][Full Text] [Related]
18. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
19. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
20. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
